Novo Nordisk slashes prices of Wegovy & Ozempic by up to 50%
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
The Japanese Patent Office has issued a favorable Appeal Decision granting a patent for the use of REQORSA Gene Therapy in combination with PD-L1 antibodies to treat cancer
For the fourth quarter, revenue surged 47% year-on-year to Rs. 2,510 million, driven by a 23% rise in domestic sales and a 9.3x jump in export sales
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
The new patents cover critical advancements in cochlear implant technology
Subscribe To Our Newsletter & Stay Updated